



PHARMACY POLICY STATEMENT Indiana Medicaid

DRUG NAME	Kymriah (tisagenlecleucel)
BILLING CODE	N/A
BENEFIT TYPE	Carved out to FFS (fee-for-service) benefit
SITE OF SERVICE ALLOWED	N/A
COVERAGE REQUIREMENTS	Please see Indiana Fee-for-Service website

Kymriah (tisagenlecleucel) is a product that is carved out from managed care benefits and is included in the Indiana Medicaid Fee-For-Service (FFS) program. Requests for coverage of this product must be submitted directly to OptumRx for review.

DATE	ACTION/DESCRIPTION
10/24/2017	New policy for Kymriah created.
05/01/2018	Carve out information added—No longer paid for by CareSource. CareSource will review authorization requests and final decision on coverage and payment will be made by IN Medicaid.
08/27/2018	New indication of Large B-cell lymphoma was added. Criteria expanded for ALL diagnosis for member's disease history requirement.
01/12/2021	Statement regarding the carved-out status created.

Effective date: 01/12/2021

Revised date: 01/12/2021